Neurobiology of cognitive impairment in Parkinson's disease

被引：6
作者：
Jellinger, Kurt A. [1 ]
机构：
[1] Inst Clin Neurobiol, A-1070 Vienna, Austria
来源：
EXPERT REVIEW OF NEUROTHERAPEUTICS | 2012年 / 12卷 / 12期
关键词：
biomarkers; clinical features; consensus guidelines; dementia with Lewy bodies; diagnostic criteria; mild cognitive impairment; neuroimaging; neuropathology; Parkinson's disease dementia; treatment options; LEWY BODY DISEASE; ALZHEIMERS ASSOCIATION GUIDELINES; CEREBRAL GLUCOSE-METABOLISM; CSF ALPHA-SYNUCLEIN; CEREBROSPINAL-FLUID; NEUROPSYCHIATRIC SYMPTOMS; DIAGNOSTIC-CRITERIA; AMYLOID-BETA; NEUROPATHOLOGIC ASSESSMENT; DEPRESSIVE SYMPTOMS;
D O I：
10.1586/ERN.12.131
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Cognitive impairment is a frequent complication of Parkinson's disease (PD). Mild cognitive impairment (MCI) may progress to dementia more frequently and rapidly. PD dementia (PDD) and PD-MCI have a mean prevalence up to 75% each; a four-to six-times increased incidence rate compared with controls. Recent diagnostic clinical criteria for both PDD and PD-MCI require validation. Cognitive decline in PD can be probed clinically, comprehensive neuropsychological assessment being the best way to define it. Neuroimaging in both disorders revealed cortical atrophy, hypometabolism, white matter changes, dopaminergic/cholinergic dysfunction and increased amyloid burden. Combined analysis of imaging and cerebrospinal fluid markers (tau and A beta-42) is the most promising method for indentifying PD-MCI and PDD. Morphological substrates are a combination of Lewy and Alzheimer pathologies causing destruction of essential neuronal networks. PDD and dementia with Lewy bodies are considered similar parts of a disease spectrum. Treatment with cholinesterase inhibitors revealed mild-to-moderate results.
引用
收藏
页码：1451 / 1466
页数：16
相关论文
共 218 条
[1]   The rate of cognitive decline in Parkinson disease [J].
Aarsland, D ;
Andersen, K ;
Larsen, JP ;
Perry, R ;
Wentzel-Larsen, T ;
Lolk, A ;
Kragh-Sorensen, P .
ARCHIVES OF NEUROLOGY, 2004, 61 (12) :1906-1911
[2]   Clinical Trials of Dementia With Lewy Bodies and Parkinson's Disease Dementia [J].
Aarsland, D. ;
Ballard, C. ;
Rongve, A. ;
Broadstock, M. ;
Svenningsson, P. .
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2012, 12 (05) :492-501
[3]  
Aarsland D, 2005, J CLIN PSYCHIAT, V66, P633
[4]   A systematic review of prevalence studies of dementia in Parkinson's disease [J].
Aarsland, D ;
Zaccai, J ;
Brayne, C .
MOVEMENT DISORDERS, 2005, 20 (10) :1255-1263
[5]   Mild cognitive impairment in Parkinson disease A multicenter pooled analysis [J].
Aarsland, D. ;
Bronnick, K. ;
Williams-Gray, C. ;
Weintraub, D. ;
Marder, K. ;
Kulisevsky, J. ;
Burn, D. ;
Barone, P. ;
Pagonabarraga, J. ;
Allcock, L. ;
Santangelo, G. ;
Foltynie, T. ;
Janvin, C. ;
Larsen, J. P. ;
Barker, R. A. ;
Emre, M. .
NEUROLOGY, 2010, 75 (12) :1062-1069
[6]   Cognitive impairment in incident, untreated Parkinson disease The Norwegian ParkWest Study [J].
Aarsland, D. ;
Bronnick, K. ;
Larsen, J. P. ;
Tysnes, O. B. ;
Alves, G. .
NEUROLOGY, 2009, 72 (13) :1121-1126
[7]   Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress [J].
Aarsland, D. ;
Bronnick, K. ;
Ehrt, U. ;
De Deyn, P. P. ;
Tekin, S. ;
Emre, M. ;
Cummings, J. L. .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2007, 78 (01) :36-42
[8]  
Aarsland Dag, 2009, Int Psychogeriatr, V21, P216, DOI 10.1017/S1041610208008612
[9]   Neuropsychiatric Symptoms in Parkinson's Disease [J].
Aarsland, Dag ;
Marsh, Laura ;
Schrag, Anette .
MOVEMENT DISORDERS, 2009, 24 (15) :2175-2186
[10]   Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial [J].
Aarsland, Dag ;
Ballard, Clive ;
Walker, Zuzana ;
Bostrom, Fredrik ;
Alves, Guido ;
Kossakowski, Katja ;
Leroi, Iracema ;
Pozo-Rodriguez, Francisco ;
Minthon, Lennart ;
Londos, Elisabet .
LANCET NEUROLOGY, 2009, 8 (07) :613-618
12345678910